Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Business Wire
The company’s DELVE™ Platform combines computation and high-throughput biology to systematically discover the therapeutic potential of proteins tuned through millennia of viral evolutionThe company emerges after three years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass.--(BUSINESS WIRE)--Flagship Pioneering, the bioplatform innovation company, today unveiled Prologue Medicines, a company unlocking the therapeutic potential of the viral proteome for the creation of powerful new medicines. Flagship has initially committed $50 million to advance the company’s Decoding Evolutionary Logic of Variant Ensembles (DELVE)™ Platform and harness its power to develop a pipeline of medicines for a wide range of diseases, with an initial focus in immunological, oncology and metabolic indications."We asked, what if we could expand beyond the functional boundaries of the human proteome by harnessing viral evolution,” said Noubar Afeyan, P
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data [Seeking Alpha]Seeking Alpha
- The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically [Yahoo! Finance]Yahoo! Finance
- Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity ManagementPR Newswire
- Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at Wedbush from $31.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 5/17/24 - Form 4
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- DNLI's page on the SEC website